Always felt that a drug for vet would undercut and even stigmatise its application for humans. Think about it. Might have been path of least resistance but it was short-sighted, a Haliday idea. Perhaps should have concentrated on human application then gone human to vet. Stelfonta developing a reputation for being challenging in its treatment presentation hasnt helped. And revenue dropping like a stone. Maybe can it as a vet drug, not worth it given the paltry revenue. So much for 100 mill VG projected. Not even 1/100 of that. Time for rebrand. Whatever vet trials they are doing should be pulled or run its course for the data only. That route has so far not proven a to be a good business decision.
